95 related articles for article (PubMed ID: 17184980)
1. [Potential for reduced intensity conditioning regimens for paediatric malignancies].
Paillard C; Bay JO; Dalle JH; Michel G; Bordigoni P; Kanold J
Arch Pediatr; 2007 Feb; 14(2):200-1. PubMed ID: 17184980
[No Abstract] [Full Text] [Related]
2. Possible role of toll-like receptor 9 polymorphism in chemotherapy-related invasive mold infections in children with hematological malignancies.
Lanciotti M; Pigullo S; Lanza T; Dufour C; Caviglia I; Castagnola E
Pediatr Blood Cancer; 2008 Apr; 50(4):944. PubMed ID: 17894360
[No Abstract] [Full Text] [Related]
3. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study.
von Lilienfeld-Toal M; Glasmacher A
Cancer; 2005 Feb; 103(4):874; discussion 875. PubMed ID: 15611970
[No Abstract] [Full Text] [Related]
5. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy of hematological malignancies based on EBM].
Ueda R
Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():147-53. PubMed ID: 11989255
[No Abstract] [Full Text] [Related]
7. [Cytostatic drug therapy in the aged].
Wilmanns W
Verh Dtsch Ges Inn Med; 1990; 96():286-94. PubMed ID: 2092446
[No Abstract] [Full Text] [Related]
8. Expression of MxA protein in blood lymphocytes of children receiving anticancer chemotherapy.
Koskenvuo MM; Halminen M; Blomqvist M; Vainionpää R; Ilonen J; Julkunen I; Salmi TT; Mäkelä MJ
Pediatr Hematol Oncol; 2006 Dec; 23(8):649-60. PubMed ID: 17065141
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
10. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Simon R; Norton L
Nat Clin Pract Oncol; 2006 Aug; 3(8):406-7. PubMed ID: 16894366
[No Abstract] [Full Text] [Related]
11. Impact of dose-intense chemotherapy on the development of permanent drug resistance.
Coldman AJ; Goldie JH
Semin Oncol; 1987 Dec; 14(4 Suppl 4):29-33. PubMed ID: 3686044
[TBL] [Abstract][Full Text] [Related]
12. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
[No Abstract] [Full Text] [Related]
13. [Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults].
Peffault de Latour R; Cabrespine-Faugeras A; Bay JO
Bull Cancer; 2008 Jan; 95(1):87-97. PubMed ID: 18230574
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the role of dose intensity in hematological malignancies.
Holmberg LA; Stewart FM
Exp Hematol; 2006 Jul; 34(7):811-25. PubMed ID: 16797408
[No Abstract] [Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
17. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
18. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
19. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
